Time to Sustained CEA Elevation From Start of First-Line Therapy Predicts Initial Treatment Efficacy and Clinical Outcomes in Lung Adenocarcinoma

In the complex landscape of lung cancer, doctors rely on a few trusted tools to gauge how a patient is faring. One of the most established of these is a blood test for a protein called carcinoembryonic antigen, or CEA. In a healthy adult, this protein is usually absent from the bloodstream. However, when lung adenocarcinoma, a common type of lung cancer, is present, the tumor cells often release it. Doctors have long used the amount of CEA in the blood as a signal: high levels suggest the cancer is active, and a drop in levels after treatment suggests the therapy is working. But for years, the focus remained on the height of the number itself, rather than the timing of its return. The question that has lingered is not just how high the level goes, but how long a patient can stay on a successful treatment before that signal begins to climb again.

A team of researchers at the Affiliated Hospital of Guangdong Medical University decided to investigate this specific timing. They looked back at the records of 225 patients with advanced lung adenocarcinoma who had just begun their first round of treatment. These patients had tumors that could not be removed by surgery and had already tested positive for CEA in their blood before treatment started. The researchers tracked these patients closely, drawing blood every four weeks to monitor their CEA levels. They were looking for a specific moment: the point where the CEA level stopped falling or staying steady and began to rise consistently. They defined this as a "sustained elevation," which occurred when two consecutive blood tests showed an increase of at least 20 percent.

The researchers measured the time from the very first day of treatment until this sustained rise happened. They called this interval the time to sustained CEA elevation. To make sense of the data, they split the patients into two groups based on how long this interval lasted. One group was defined by a specific threshold of 134 days, while another comparison used the middle point of all the patients' times, which was 242 days. The goal was to see if the length of this waiting period predicted how well the patients would do in the long run.

The findings were clear and consistent. Patients who waited a long time before their CEA levels began to rise consistently fared significantly better than those whose levels rose quickly. Those who reached the 134-day mark without a sustained rise had a much higher chance of their tumors shrinking or staying under control compared to those whose levels rose before that time. This pattern held true even when the researchers looked at the longer 242-day mark. The patients with the longer wait times lived longer without their disease getting worse, and they also lived longer overall. In fact, the difference was stark: patients who waited at least 134 days lived a median of 32 months, while those whose levels rose sooner lived a median of only 14 months. When the researchers looked at the 242-day split, the gap widened further, with the longer-wait group living a median of 35 months compared to 18 months for the shorter-wait group.

The study also confirmed that other factors played a role in a patient's outcome. Patients with liver metastases, meaning the cancer had spread to the liver, faced a higher risk of the disease progressing and a higher risk of death, regardless of how long their CEA levels stayed stable. Conversely, being female was associated with a lower risk of the disease progressing quickly. However, the time it took for the CEA to rise remained a powerful predictor on its own. Even after accounting for gender, the presence of liver metastases, the type of treatment received, and the specific genetic mutations in the tumor, the length of the interval before the CEA rose continued to stand out as an independent sign of the patient's future.

This research suggests that the timing of a rising CEA level is not just a side note but a critical piece of information. It acts like a clock that measures how long the initial treatment is successfully holding the cancer at bay. A longer time before the signal returns indicates that the treatment is working deeply and durably, delaying the emergence of resistant cancer cells. A short time suggests the cancer is adapting quickly. The researchers propose that doctors could use this timeline to make smarter decisions. If a patient's CEA levels begin to rise consistently before the 134-day or 242-day marks, it might be a signal to check the patient more frequently or to consider changing the treatment plan sooner, rather than waiting for a scan to show the tumor has grown.

The study was conducted by reviewing past records, which means it reflects real-world outcomes but cannot prove cause and effect with the same certainty as a new experiment. The researchers noted that their findings apply specifically to patients who started with detectable CEA levels and that the exact timing thresholds might need to be tested in other groups of people. They also pointed out that combining this timing information with other modern tools, such as genetic testing or other blood markers, could provide an even clearer picture. For now, the work offers a new way to listen to the body's signals, suggesting that how long a patient can keep their CEA levels steady is a strong indicator of how much time they have ahead of them.